

1 **Characterization of *V. cholerae* O1 isolates responsible for cholera outbreaks in Kenya**  
2 **between 1975 and 2017**

3  
4 Martin Bundi<sup>1,2,3\*</sup>, Mohammad Monir Shah<sup>1,5\*</sup>, Eric Odoyo<sup>1</sup>, Cyrus Kathiiko<sup>1</sup>, Ernest Wandera<sup>1</sup>,  
5 Gabriel Miring'u<sup>1</sup>, Sora Guyo<sup>1</sup>, Daniel Langat<sup>4</sup>, Kouichi Morita<sup>2,6</sup>, Yoshio Ichinose<sup>1,2</sup>

6  
7 <sup>1)</sup> Department of Bacteriology, NUITM-KEMRI Project, Kenya Research Station, Institute of  
8 Tropical Medicine, Nagasaki University, Nairobi, Kenya

9 <sup>2)</sup> Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

10 <sup>3)</sup> National Biosafety Authority, Nairobi, Kenya

11 <sup>4)</sup> Ministry of Health, Disease Surveillance and Response Unit, Nairobi, Kenya

12 <sup>5)</sup> Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University,  
13 Nagasaki, Japan

14 <sup>6)</sup> Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

15  
16 **Address correspondence to:** Martin Bundi or Mohammad Monir Shah,  
17 NUITM-KEMRI Project, Nagasaki University Institute of Tropical Medicine, Kenya Research  
18 Station, P.O. Box 19993-00202 Nairobi, Kenya. Tel: +254-20-272-5120; Fax: +254-20-272-5144  
19 E-mail: bundimartin@gmail.com (M. Bundi) or shah@nagasaki-u.ac.jp (M.M. Shah)

20  
21 **Short running title:** Cholera outbreaks in Kenya, 1975-2017

22  
23 **Subject section:** Bacteriology; **Specified field:** Epidemiology

24 **ABSTRACT**

25 Kenya is endemic for cholera with different waves of outbreaks having been documented since  
26 1971. In recent years, new variants of *V. cholerae* O1 have emerged and replaced most of the  
27 traditional El Tor biotype globally. These strains also appear to have increased virulence, and it is  
28 important to describe and document their phenotypic and genotypic traits. In this study, we  
29 characterized 146 *V. cholerae* O1 isolates from cholera outbreaks that occurred in Kenya between  
30 1975 and 2017. Our study reports that the 1975-1984 strains had typical classical or El Tor biotype  
31 characters. New variants of *V. cholerae* O1 having traits of both classical and El Tor biotypes were  
32 observed from 2007 with all strains isolated between 2015 and 2017 being sensitive to polymyxin  
33 B and carrying both classical and El Tor type *ctxB*. All strains were resistant to Phage IV and  
34 harbored *rstR*, *rtxC*, *hlyA*, *rtxA* and *tcpA* genes specific for El Tor biotype indicating that the strains  
35 had an El Tor backbone. Pulsed Field Gel Electrophoresis (PFGE) genotyping differentiated the  
36 isolates into 14 pulsotypes. The clustering also corresponded with the year of isolation signifying  
37 that the cholera outbreaks occurred as separate waves of different genetic fingerprints exhibiting  
38 different genotypic and phenotypic characteristics. We report the emergence and prevalence of *V.*  
39 *cholerae* O1 strains carrying El Tor type and classical type of *ctxB* in Kenya. These strains have  
40 replaced the typical El Tor biotype in Kenya and are potentially more virulent and easily  
41 transmitted within the population.

42

43 **Keywords:** *Vibrio cholerae* O1, cholera outbreaks, biotyping, Pulsed-field gel electrophoresis

## 44 INTRODUCTION

45 Cholera is an infectious disease caused by *Vibrio cholerae* O1 and O139, and its pandemic  
46 continues to occur in much of the developing world with Africa being the most affected continent  
47 (1). The disease is endemic in Kenya, and several waves of outbreaks have been reported since  
48 1971 (2). According to the World Health Organization (WHO), from 1974 to 1989, Kenya reported  
49 cases every year, with an average case fatality rate (CFR) of 3.57% (3). Between 1997 to 2010, a  
50 total of 68,522 clinically suspected cases of cholera and 2,641 deaths were reported (CFR=3.9%)  
51 (4). In 2005, a total of 990 cases and 25 deaths (CFR=2.5%) were reported in five distinct outbreaks,  
52 including 186 laboratory-confirmed cases (5). Between January 2015 to January 2016, a total of  
53 11,033 cases were reported with 178 deaths (CFR=1.6%) in 22 of 47 counties (6).

54  
55 *V. cholerae* is classified into approximately 206 serogroups of which, O1 and O139 produce  
56 cholera toxin associated with cholera pandemics (7). The O1 serogroup is further divided into three  
57 serotypes, namely Inaba, Ogawa, and Hikojima and two biotypes, namely classical and El Tor. *V.*  
58 *cholerae* O1 can be phenotypically characterized based on a number of phenotypic traits such as  
59 susceptibility to polymyxin B (50U), chicken erythrocyte agglutination, hemolysis of sheep  
60 erythrocytes, the Voges-Proskauer (VP) test which measures the production of  
61 acetylmethylcarbinol, and sensitivity of specific bacteriophages (8). The El Tor strains are resistant  
62 to polymyxin B (50U), VP test positive, agglutinate chicken erythrocytes and are resistant to the  
63 classical bacteriophage IV. Classical strains show reverse traits (8).

64  
65 The two biotypes can also be distinguished using molecular biotyping methods (9). The cholera  
66 toxin (CT) is the primary toxin produced by *V. cholerae* O1 and O139 and is mostly responsible

67 for the manifestations of cholera. The *ctxAB* gene, which is located in the CTX prophage of the *V.*  
68 *cholerae* chromosome encodes the cholera toxin (9). The classical toxin (CT1) is produced by  
69 classical strains and US Gulf Coast strains, whereas the El Tor type toxin (CT2) is produced by the  
70 El Tor and O139 strains (10). The two toxins differ in the cholera toxin B subunit and a mismatch  
71 amplification mutation PCR assay (MAMA) PCR has been used to differentiate between the  
72 classical type *ctxB* and El Tor type *ctxB* (11). The Vibrio Pathogenicity Island-1 (VPI-1) DNA  
73 region of the large chromosome is composed of the toxin-coregulated pilus (TCP) and the  
74 accessory colonization factor (ACE). The *tcpA* gene of the TCP cluster has alleles that are specific  
75 to the classical and El Tor biotypes and can be determined using specific primers (12). The CTX $\Phi$   
76 of El Tor and O139 strains are flanked by a genetic element designated RS1 (13, 14). RS1 differs  
77 from RS2 in that the *rstC* gene is contained in RS1 alone (13). *V. cholerae* also secretes several  
78 “accessory” toxins including the repeat toxin (RTX) which encodes for a cytotoxic activator protein  
79 and is composed of four open reading frames (ORFs) of which only the *rtxC* gene is found in the  
80 El Tor biotypes (9, 15). The *hlyA* gene encodes for the hemolysin encoding gene, which differs in  
81 nucleotide sequence between the El Tor and classical strains (12).

82  
83 Over the last few decades, new variants of *V. cholerae* have emerged that cannot be typed using  
84 the current biotyping scheme. Nair *et al.* (16) identified strains of *V. cholerae* O1 El Tor with  
85 classical biotype traits from patients in Bangladesh. They termed the strains as “hybrid type” strain  
86 since they could not be biotyped. Due to the limitations in the currently used biotyping scheme,  
87 Raychoudhuri *et al.* proposed a revised biotyping scheme for *V. cholerae* O1 that incorporates  
88 hybrid biotypes and the El Tor variant strains (8). With the emergence of new variants of *V.*  
89 *cholerae* globally, it is important to characterize strains isolated from Kenyan outbreaks and

90 determine how they compare with these strains. A study by Kiiru *et al.* (17) characterized 65 *V.*  
91 *cholerae* O1 strains isolated in Kenya between 1994 and 2007 and identified the strains as El Tor  
92 biotype lacking any classical biotype markers. Another study reported that strains isolated between  
93 2007 and 2010 were biotype El Tor variants possessing the cholera toxin B subunit gene and were  
94 positive for the *ctxA*, *tcpA* of El Tor biotype and *rtxC* genes (18). However, their evolutionary  
95 lineage and how they compare with other strains previously isolated from other countries where  
96 cholera is endemic has not been described. This study aimed to describe the evolving phenotypic  
97 and genotypic traits of *V. cholerae* O1 strains that were collected over the last four decades in  
98 Kenya and other Asian countries where cholera outbreaks are prevalent.

99

## 100 **MATERIALS AND METHODS**

### 101 **Ethics statement**

102 The strains used in this study were isolated and stocked during previous studies. The study was  
103 approved by the KEMRI Scientific and Ethics Review Unit (SERU) SSC No. 1323 and the ethical  
104 committee of Nagasaki University Graduate School of Biomedical Sciences.

105

### 106 **Description of cholera strains**

107 A total of 146 *V. cholerae* O1 stocked strains isolated from patients during cholera outbreaks in  
108 Kenya between 1975 and 2017 were analysed in this study (Table 1). The strains were collected  
109 during surveillance programs by the Nagasaki University, Institute of Tropical Medicine, Kenya  
110 Research Station (NUITM-KEMRI) following requests from the Kenya Ministry of Health and  
111 other local health centers. These strains were grouped into three categories based on the period  
112 when they were isolated with 1975-1984 (36 strains) representing the entry of cholera into Kenya,

113 2007-2010 (37 strains) representing the period when variants of *V. cholerae* were reported in the  
114 country, and 2015-2017 (66 strains) representing the most recent outbreaks in the country. Selected  
115 isolates from several Asian countries isolated between 1958 and 2010 (19 strains) were also  
116 included in this study for comparison (Table 2). The strains were donated by the institute's partners  
117 in the collaborating countries and stocked at NUITM, Nagasaki, Japan. The El Tor biotype K-23  
118 strain and classical biotype 569B and H218 reference strains were used as controls. All strains were  
119 confirmed as *V. cholerae* O1 by standard biochemical tests and serology (19, 20).

120

### 121 **Biotyping of cholera strains**

122 Phenotypic tests for biotype determination included hemolysis of sheep red blood cells as described  
123 by Feeley and Pittman (21), sensitivity to polymyxin B by the E-test strip method with sensitive  
124 strains having a MIC of  $\leq 2$   $\mu\text{g/mL}$ , sensitivity to classical phage IV as described by S. Mukerjee  
125 (22), the VP test which measures the production of acetylmethylcarbinol (23), and the  
126 hemagglutination of chicken erythrocytes (24).

127

128 Genotypic tests complemented the phenotypic tests and included Polymerase Chain Reaction  
129 (PCR) assays targeting various virulence and biotype determining genes. Primer sets *ctxA* (25), and  
130 *tcpA* (12) were used to detect the major virulence factors of pathogenic *V. cholerae*, cholera toxin  
131 (CT) and toxin coregulated pili (TCP). Other virulence genes assayed included *toxR* (26), *rstC* (27),  
132 *rtxA* (28) and *hlyA* (12). Primer sets *ctxB* (11), *hlyA* (12), *rstC* (27), *rstR* (29), *rtxC* (28), and *tcpA*  
133 (12) were used to detect classical and El Tor biotype specific alleles in the strains.

134

135 Results from at least three phenotypic tests and all genotypic tests were used to determine the  
136 strain's biotype as either "classical", "El Tor", "El Tor variant" or "hybrid" as described by  
137 Raychoudhuri *et al* (8). Strains that could not be biotyped according to this criteria were termed  
138 "unclassified".

139

#### 140 **Polymerase Chain Reaction (PCR)**

141 Genomic DNA extraction was performed by the phenol-chloroform–isoamyl alcohol extraction  
142 method as described by Huq *et al.* (30) and PCR performed using PuReTaq ready-to-go PCR beads  
143 as per the manufacturer's instructions (GE Healthcare UK limited, UK). The PCR products were  
144 analysed by electrophoresis on 2.5% agarose gels, stained with ethidium bromide, visualized under  
145 UV light and recorded with the aid of a gel documentation system (E-BOX 1000, Vilber Lourmat,  
146 Marne-la-Vallee, France).

147

#### 148 **Pulsed-field Gel Electrophoresis (PFGE)**

149 Twenty-six isolates randomly selected based on their identified biotype and year of isolation (Table  
150 1) were analyzed using the PulseNet standardized pulsed-field gel electrophoresis (PFGE) protocol  
151 for *V. cholerae* (31) with slight modifications. The genomic DNA was restricted with 50U of *NotI*  
152 restriction enzyme (Takara Bio Inc., Shiga, Japan) at 37°C for 4 hours and electrophoresis run using  
153 a CHEF-DRIII system (Bio-Rad, USA). Gel images were captured on a Gel documentation system  
154 (E-BOX 1000, Vilber Lourmat, Marne-la-Vallee, France) and the restriction patterns analysed  
155 using BioNumerics software V7.6 (Applied Maths, Inc., Belgium). The Dice similarity coefficient  
156 determined the banding similarity with a 1.0% band matching tolerance, and a dendrogram  
157 constructed using the unweighted-pair group method with arithmetic mean algorithm (UPGMA).

158

159 **RESULTS**160 *Epidemiology:*

161 Different serotypes of *V. cholerae* O1 were isolated in each wave of cholera outbreaks. All strains  
162 isolated between 1975 and 1984 were Ogawa type whereas those isolated between 2007 and 2009  
163 were Inaba type. Between the years 2007 and 2010, the predominant serotype was Inaba. The 2010  
164 outbreaks occurred in Kwale and Pokot Counties of Kenya. Serotype Ogawa emerged in 2010 in  
165 Kwale county cholera outbreaks and prevailed from 2015 to 2017. Most strains carried pathogenic  
166 genes for *V. cholerae* O1 with 90% (131/146) of the strains being positive for subunit A of cholera  
167 toxin gene (*ctxA*), 89% (130/146) positive for toxin-coregulated pilus gene (*tcpA*) and the *rstC*  
168 antirepressor. All strains carried the toxin-coregulated pilus (*toxR*), repeat in toxin RTX (*rtxA*), and  
169 the hemolysin A (*hlyA*) virulence genes (Table 3).

170

171 *Phenotypic tests:*

172 Based on the phenotypic test results for biotype determination as described in Table 1, all strains  
173 were resistant to phage IV, a trait exhibited by El Tor biotype strains. Chicken erythrocytes  
174 agglutination test results showed variable results for the 1975-1984 strains. Ninety-five point five  
175 percent (105/110) of strains isolated between 2007 and 2017 were positive for this test. Strains  
176 isolated between 1975 and 1984 were resistant to polymyxin B and had a minimal inhibitory  
177 concentration (MIC) of  $> 2\mu\text{g/mL}$  based on the E-test method. The results were similar to those of  
178 typical El Tor biotype strains. Seventy-five percent of the 2007 strains, 93% of the 2015 strains  
179 and all of the 2016 and 2017 strains were sensitive to polymyxin B, results similar to those for the



180 classical biotype strains. Variable results were observed for the VP and Sheep red blood cell  
181 hemolysis tests (Table 1).

182

183 *Genotypic tests:*

184 According to the genotypic test results for biotype determination as described in Table 1, all of the  
185 146 *V. cholerae* O1 strains carried the hemolysin encoding gene (*hlyA*) specific for the El Tor  
186 biotype. Our study also analyzed 19 *V. cholerae* O1 strains isolated from Asian countries between  
187 1961 and 2010 and classified these strains as either classical biotype, El Tor biotype or El Tor  
188 variant biotype possessing classical *ctxB* (Table 2). Results of the other biotype determination PCR  
189 assays showed that all strains possessed the El Tor biotype markers for the hemolysin encoding  
190 gene (*hlyA*) while a majority possessed the repeat-sequence transcriptional regulator gene (*rstR*),  
191 *rtxC* gene of the RTX toxin gene cluster, and the toxin-coregulated pilus (TCP) gene (*tcpA*) specific  
192 for the El Tor biotype.

193

194 *Pulsed Field gel electrophoresis (PFGE):*

195 PFGE analysis of *NotI* digested genomic DNA differentiated the isolates into 14 pulsotypes (Figure  
196 1). UPGMA differentiated the isolates into 2 clusters (I and II) at 82% similarity cut off and five  
197 sub-groups (A-E) at 94% similarity cut off. A general association between the period of the  
198 outbreaks and the cluster subgroups was observed. Strains isolated between 1975 and 1984 were  
199 clustered in cluster I (sub-group A-C). Those isolated between 2007 and 2010 were clustered in  
200 cluster II (sub-group D) except for one strain. Isolates from the most recent outbreaks in the country  
201 (2015-2017) were clustered in cluster II (sub-group E). Another observed association was between  
202 the biotypes. El Tor biotype strains isolated between 1975 and 1984 were grouped in cluster I (sub-

203 group A-C) whereas atypical El Tor strains occurring between 2007 and 2017 were grouped in  
204 cluster II.

205  
206 In 2010, strains isolated in Kwale County were of serotype Ogawa while those of Pokot serotype  
207 Inaba. One strain from Pokot (Pulsotype D6) showed 98% similarity with two Kwale strains  
208 (Pulsotype D3). Another interesting observation was that one strain of serotype Inaba isolated in  
209 Pokot in 2010 that harbored both classical and El Tor type *ctxB* showed 100% similarity with two  
210 serotype Ogawa strains isolated in 2015 and 2016 and 99% similarity with the other 2015-2017  
211 strains.

212

## 213 **DISCUSSION**

214 In this study, we characterized 146 *V. cholerae* O1 strains isolated during cholera outbreaks that  
215 occurred in Kenya between 1975 and 2017 by analyzing their phenotypic and genetic traits and  
216 comparing this data with genotypic data of representative strains of several Asian countries. Of the  
217 five phenotypic tests, the phage IV resistance test yielded the most stable results and classified the  
218 strains as El Tor biotype. Voges-Proskauer (VP) and chicken cell agglutination test result classified  
219 the 1975-1984 *V. cholerae* O1 isolates as typical El Tor biotype and the rest as having both classical  
220 and El Tor traits. Results of the Phage IV test were consistent with those previously reported in  
221 Kenya (32) demonstrating the stability of this test. In a study done by Safa *et al.* (33) where they  
222 analysed the phenotypic and genotypic traits of various *V. cholerae* O1 strains, the Phage IV test  
223 was able to discriminate between classical and El Tor biotypes. Our results of the sheep erythrocyte  
224 hemolysis test were consistent with those reported elsewhere where the test has been reported to  
225 be of limited use since the El Tor strains lost their hemolytic activity in the late 1960's yielding

226 variable results (19). Previous cholera studies in Kenya in 1983 (32) and 2007-2010 (18) outbreak  
227 strains as being reported as polymyxin B resistant. Results from this study demonstrate that  
228 polymyxin B sensitive strains emerged in Kenya in the mid-2000s and completely replaced  
229 polymyxin B resistant strains by the year 2016. Polymyxin B susceptible El Tor biotype strains  
230 have also been reported in other countries (16, 31). We found that phenotypic tests for biotype  
231 determination can classify the 1975-1984 isolates as El Tor biotype and the rest of the strains as  
232 having features of both classical or El Tor biotypes.

233

234 Besides of phenotypic test, genetic characterization including PCR analysis of biotyping genes can  
235 determine the isolates biotypes. The classical toxin (CT1) is produced by classical strains and US  
236 Gulf Coast strains, whereas the El Tor type toxin (CT2) is produced by the El Tor and O139 strains  
237 (10). The results of the mismatch amplification mutation PCR assay (MAMA) PCR (11) that  
238 differentiates between the classical type *ctxB* and El Tor type *ctxB* revealed the emergence of strains  
239 carrying both the classical and El Tor *ctxB* in 2007. All strains isolated between 1975-1984 had El  
240 Tor *ctxB*, 75% (33/44) of the 2007-2010 isolates and 94% (62/66) of 2015-2017 isolates carried  
241 both classical and El Tor *ctxB*. Probably these strains might have evolved from El Tor variants that  
242 acquired specific attributes from the classical genome. The other biotype determination PCR assays  
243 (*rstR*, *rtxC*, *hlyA*, *rtxA*, and *tcpA* genes specific for the classical or El Tor biotype) showed that all  
244 strains possessed the El Tor biotype markers and none was positive for the classical biotype  
245 indicating that the strains had an El Tor backbone. A previous study that characterized 65 *V.*  
246 *cholerae* O1 strains isolated in Kenya between 1994 and 2007 identified the strains as El Tor  
247 biotype lacking any classical biotype markers (17). However, several studies have reported El Tor  
248 variant strains producing cholera toxin of the classical biotype (10, 20, 31) with some studies

249 indicating that they produce higher levels of cholera toxin than the classical biotype strains (30). A  
250 study conducted in India reported the emergence of strains producing both classical and El Tor  
251 *ctxB* in 1991 and 1992, but these were replaced by classical type *ctxB* strains in subsequent years  
252 (34).

253  
254 Classical and El Tor biotypes differ in not only their phenotypic and genotypic properties, but also  
255 their pathogenic potentials, survivability, and infection patterns in the hosts (35). We found that  
256 71% of the isolates carried the *V. cholerae* virulence factors *ctxA*, *tcpA*, *toxR*, *rstC*, *rtxA*, and *hlyA*  
257 confirming the toxin-producing capability and endemic potential of these strains. The *rtxA*, *toxR*,  
258 and *hlyA* virulence genes were carried in all the strains suggesting their importance in pathogenicity  
259 of *V. cholerae* more so in strains that lacked the *ctxA* gene.

260  
261 Our study indicates that serotype Ogawa caused cholera outbreaks occurring between 1975 and  
262 1984, and those from 2007-2009 were serotype, Inaba. This was in agreement with previous reports  
263 in the country (4, 17, 32). Serotype Ogawa reemerged in 2010 and replaced serotype Inaba in the  
264 2015-2017 cholera outbreaks. The serotype switching from O1 Ogawa to Inaba and vice versa is  
265 common in many cholera-endemic areas (36). It has been attributed to a change in the genetic  
266 make-up of the *wbtT* gene that determines the Ogawa specificity (37-38). Serotype conversion in  
267 endemic strains has been linked to environmental factors and immune pressure within the  
268 population (38-40).

269  
270 The results of the phenotypic and genetic characterization reveal that earlier strains isolated in  
271 Kenya from 1975-1984 had typical El Tor characters, which is in agreement with previous studies

272 done in Kenya (32). Cholera outbreaks occurring between 2007 and 2017 were caused by new  
273 variants of *V. cholerae* O1 that had traits of both the classical and El Tor biotypes and were  
274 classified as hybrid type, El Tor variants, or unclassified (for those that did not fit in any category).  
275 In order to understand the Kenyan isolates, we compared *V. cholerae* O1 strains with other  
276 countries and biotyped representative strains isolated from several Asian countries. Phenotypic and  
277 PCR analysis classified them as either classical type, typical El Tor, or El Tor variants justifying  
278 the occurrence of altered *V. cholerae* O1 strains in other parts of the World (8, 10, 16, 33). None  
279 of the strains carried both classical and El Tor *ctxB* (Table 2). We report the emergence of *V.*  
280 *cholerae* O1 strains carrying both the classical and El Tor *ctxB* in Kenya. Kenya has been reporting  
281 severe cholera outbreaks in different waves since 2007 which coincides with the emergence of  
282 these new variants. The acquisition of cholera toxin of the classical type in addition to that of El  
283 Tor type potentially makes them more virulent, persistent in the environment, and easily  
284 transmissible within the population.

285  
286 A review of the study by Weill *et al.* (1) shows that cholera epidemics were introduced in Africa  
287 by a single expanded lineage since 1970. Specifically, the T5 event was introduced in 1970 and  
288 transmitted cholera within Kenya between 1980-1989 during the first wave of global cholera  
289 transmission. Wave 2 involved T6 event which was introduced in the continent between 1986 and  
290 1989 and occurred in Kenya between 1990 and 1999. Wave 3 was associated with T10 event which  
291 was introduced in Africa during 1991-1995 and transmitted in Kenya between 1990 and 2014. A  
292 study by Mutreja *et al.* (41) reported the transmission of the 7th pandemic from the Bay of Bengal  
293 in three independent waves with wave 1 reaching Kenya between 1973-1985 and wave 3 between  
294 1989-1997. Our PFGE results differentiated the strains into two distinct clusters (cluster 1: 1975-

295 1984 strains; and cluster 2: 2007-2017 strains). The clustering also corresponded with the year of  
296 isolation signifying that the cholera outbreaks occurred as separate waves of different genetic  
297 fingerprints exhibiting different genotypic and phenotypic characteristics. There is a need to  
298 perform whole genome sequencing on *V. cholerae* outbreak strains isolated in Kenya to determine  
299 their location in the genomic history of African cholera.

300  
301 In summary, we report the emergence of *V. cholerae* O1 strains sensitive to polymyxin B and  
302 harboring both classical and El Tor type *ctxB*. The strains had an El Tor biotype backbone as they  
303 possessed *rstR*, *rtxC*, *hlyA*, *rtxA*, and *tcpA* El Tor biotype markers. This change is a significant  
304 event in cholera epidemics in Kenya as few countries have reported the circulation of virulent *V.*  
305 *cholerae* O1 strains harboring both classical and El Tor type *ctxB* and sensitive to polymyxin B.  
306 The isolation of virulent atypical *V. cholerae* O1 strains and the frequent cholera outbreaks in the  
307 country calls for further investigation to determine their clinical and epidemiologic significance.  
308 This information could be useful in understanding the characterization and evolution of *V. cholerae*  
309 and for the management of cholera outbreaks associated with new variants of *V. cholerae* O1.

310

### 311 **ACKNOWLEDGEMENTS**

312 This work was supported in part by the Japanese Society for the Promotion of Science (JSPS,  
313 RONPAKU program). We acknowledge Applied Maths for their support during evaluation of the  
314 Bionumerics software package and also thank the director of the Kenya Medical Research Institute  
315 (KEMRI), the director Centre for Microbiology Research (CMR-KEMRI), and the Kenya Ministry  
316 of Health for continuously supporting the activities of our institute. We are grateful to the National  
317 Public Health Laboratories, Kenya for the collaboration during cholera outbreaks in the country.

318 We also acknowledge the other staff of NUITM-KEMRI and the top management of National  
319 Biosafety Authority for their support during this study.

320

## 321 **DISCLOSURE**

322 The authors have no conflict of interest to declare.

323

## 324 **REFERENCES**

- 325 1. Weill F.X., Domman D., Njamkepo E., Tarr C., Rauzier J., Fawal N., Keddy K.H., Salje H.,  
326 Moore S., Mukhopadhyay A.K., Bercion R., Luquero F.J., Ngandjio A., Dosso M., Monakhova  
327 E., Garin B., Bouchier C., Pazzani C., Mutreja A., Grunow R., Sidikou F., Bonte L., Breurec  
328 S., Damian M., Njanpop-Lafourcade B.M., Sapriel G., Page A.L., Hamze M., Henkens M.,  
329 Chowdhury G., Mengel M., Koeck J.L., Fournier J.M., Dougan G., Grimont P.A.D., Parkhill  
330 J., Holt K.E., Piarroux R., Ramamurthy T., Quilici M.L., Thomson N.R. (2017) Genomic  
331 history of the seventh pandemic of cholera in Africa. *Science* 358:785-789.
- 332 2. Scrase M., Maimone F., Mohamud K., Materu S., Grimont F., Grimont P., Pazzani C. (2006)  
333 Clonal relationship among *Vibrio cholerae* O1 El Tor strains causing the largest cholera  
334 epidemic in Kenya in the late 1990s. *J Clin Microbiol* 44: 3401-3404.
- 335 3. World Health Organization. Cholera country profile: Kenya. 2010.  
336 <https://www.who.int/cholera/countries/KenyaCountryProfile2010.pdf?ua=1>.
- 337 4. Mutonga D., Langat D., Mwangi D., Tonui J., Njeru M., Abade A., Irura Z., Njeru I., Dahlke  
338 M. (2013) National surveillance data on the epidemiology of cholera in Kenya, 1997–2010. *J*  
339 *Infect Dis* 208 Suppl 1: S55-61.

- 340 5. Mugoya I., Kariuki S., Galgalo T., Njuguna C., Omollo J., Njoroge J., Kalani R., Nzioka C.,  
341 Tetteh C., Bedno S. (2008) Rapid spread of *Vibrio cholerae* O1 throughout Kenya, 2005. *Am*  
342 *J Trop Med Hyg* 78: 527-533.
- 343 6. George G. (2016) Notes from the field: ongoing cholera outbreak-Kenya, 2014-2016. *MMWR*  
344 *Morb Mortal Wkly Rep* 65: 68-69.
- 345 7. Siriphap A., Leekitcharoenphon P., Kaas R.S., Theethakaew C., Aarestrup F.M., Sutheinkul O.,  
346 Hendriksen R.S. (2017) Characterization and genetic variation of *Vibrio cholerae* isolated from  
347 clinical and environmental sources in Thailand. *PLoS One* 12:e0169324
- 348 8. Raychoudhuri A., Mukhopadhyay A., Ramamurthy T., Nandy R., Takeda Y., Nair G.B. (2008)  
349 Biotyping of *Vibrio cholerae* O1: time to redefine the scheme. *Indian J Med Res* 128: 695-698.
- 350 9. Dziejman M., Balon E., Boyd D., Fraser C.M., Heidelberg J.F., Mekalanos J.J. (2002)  
351 Comparative genomic analysis of *Vibrio cholerae*: genes that correlate with cholera endemic  
352 and pandemic disease. *Proc Nat Acad Sci* 99: 1556-1561.
- 353 10. Nair G.B., Qadri F., Holmgren J., Svennerholm A.-M., Safa A., Bhuiyan N.A., Ahmad Q.S.,  
354 Faruque S.M., Faruque A., Takeda Y. (2006) Cholera due to altered El Tor strains of *Vibrio*  
355 *cholerae* O1 in Bangladesh. *J Clin Microbiol* 44: 4211-4213.
- 356 11. Morita M., Ohnishi M., Arakawa E., Bhuiyan N., Nusrin S., Alam M., Siddique A., Qadri F.,  
357 Izumiya H., Nair G.B. (2008) Development and validation of a mismatch amplification  
358 mutation PCR assay to monitor the dissemination of an emerging variant of *Vibrio cholerae*  
359 O1 biotype El Tor. *Microbiol Immunol* 52: 314-317.
- 360 12. Rivera I.N., Chun J., Huq A., Sack R.B., Colwell R.R. (2001) Genotypes associated with  
361 virulence in environmental isolates of *Vibrio cholerae*. *Appl Environ Microbiol* 67: 2421-2429.



- 362 13. Waldor M.K., Rubin E.J., Pearson G.D., Kimsey H., Mekalanos J.J. (1997) Regulation,  
363 replication, and integration functions of the *Vibrio cholerae* CTX $\Phi$  are encoded by region RS2.  
364 *Mol Microbiol* 24: 917-926.
- 365 14. Davis B.M., Moyer K.E., Boyd E.F., Waldor M.K. (2000) CTX prophages in classical biotype  
366 *Vibrio cholerae*: functional phage genes but dysfunctional phage genomes. *J Bacteriol* 182:  
367 6992-6998.
- 368 15. Safa A., Bhuyian N., Nusrin S., Ansaruzzaman M., Alam M., Hamabata T., Takeda Y., Sack  
369 D.A., Nair G.B. (2006) Genetic characteristics of Matlab variants of *Vibrio cholerae* O1 that  
370 are hybrids between classical and El Tor biotypes. *J Med Microbiol* 55: 1563-1569.
- 371 16. Nair G.B., Faruque S.M., Bhuiyan N., Kamruzzaman M., Siddique A., Sack D.A. (2002) New  
372 variants of *Vibrio cholerae* O1 biotype El Tor with attributes of the classical biotype from  
373 hospitalized patients with acute diarrhea in Bangladesh. *J Clin Microbiol* 40: 3296-3299.
- 374 17. Kiiru J.N., Saidi S.M., Goddeeris B.M., Wamae N.C., Butaye P., Kariuki S.M. (2009)  
375 Molecular characterisation of *Vibrio cholerae* O1 strains carrying an SXT/R391-like element  
376 from cholera outbreaks in Kenya: 1994-2007. *BMC Microbiol* 9: 275.
- 377 18. Mercy N., Mohamed A.A., Ng'ang'a Zipporah G.C., Pazhani G.P., Ramamurthy T., Boga H.I.,  
378 Kariuki S.M., Joseph O. (2014) Phenotypic and genetic characterization of *Vibrio cholerae* O1  
379 isolated from various regions of Kenya between 2007 and 2010. *Pan Afr Med* 19: 8.
- 380 19. Sakazaki R, Shimada T. (1977) Serovars of *Vibrio cholerae* identified during 1970-1975. *Jpn*  
381 *J Med Sci Biol* 30: 279-282.
- 382 20. Sakazaki R., Tamura K., Gomez C.Z., Sen R. (1970) Serological studies on the cholera group  
383 of vibrios. *Jpn J Med Sci Biol* 23: 13-20.

- 384 21. Feeley J.C., Pittman M. (1963) Studies on the haemolytic activity of El Tor vibrios. *Bull World*  
385 *Health Organ* 28: 347-356.
- 386 22. Mukerjee S. (1963) The bacteriophage-susceptibility test in differentiating *Vibrio cholerae* and  
387 *Vibrio el tor*. *Bull World Health Organ* 28: 333-336.
- 388 23. World Health Organization. (1987) Manual for Laboratory Investigations of Acute Enteric  
389 Infections. Programme for Control of Diarrhoeal Disease, (CDD/83.3 Rev. 1, 1987) Geneva:  
390 World Health Organization.
- 391 24. Barua D., Mukherjee A.C. (1965) Haemagglutinating Activity of El Tor Vibrios and its Nature.  
392 *Indian J Med Res* 53: 399-404.
- 393 25. Nandi B., Nandy R.K., Mukhopadhyay S., Nair G.B., Shimada T., Ghose A.C. (2000) Rapid  
394 method for species-specific identification of *Vibrio cholerae* using primers targeted to the gene  
395 of outer membrane protein OmpW. *J Clin Microbiol* 38: 4145-4151.
- 396 26. Miller V.L., Taylor R.K., Mekalanos J.J. (1987) Cholera toxin transcriptional activator ToxR  
397 is a transmembrane DNA binding protein. *Cell* 48: 271-279.
- 398 27. Nguyen B.M., Lee J.H., Cuong N.T., Choi S.Y., Hien N.T., Anh D.D., Lee H.R.,  
399 Ansaruzzaman M., Endtz H.P., Chun J. (2009) Cholera outbreaks caused by an altered *Vibrio*  
400 *cholerae* O1 El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007 to  
401 2008. *J Clin Microbiol* 47: 1568-1571.
- 402 28. Lee J.H., Choi S.Y., Jeon Y.S., Lee H.R., Kim E.J., Nguyen B.M., Hien N.T., Ansaruzzaman  
403 M., Islam M.S., Bhuiyan N.A. (2009) Classification of hybrid and altered *Vibrio cholerae*  
404 strains by CTX prophage and RS1 element structure. *J Microbiol* 47: 783-788.
- 405 29. Chow K., Ng T., Yuen K., Yam W. (2001) Detection of RTX toxin gene in *Vibrio cholerae* by  
406 PCR. *J Clin Microbiol* 39: 2594-2597.

- 407 30. Huq A., Haley B.J., Taviani E., Chen A., Hasan N.A., Colwell R.R. (2012) Detection, isolation,  
408 and identification of *Vibrio cholerae* from the environment. *Curr Protoc Microbiol* 6A.5.
- 409 31. Cooper K., Luey C., Bird M., Terajima J., Nair G., Kam K., Arakawa E., Safa A., Cheung D.,  
410 Law C. (2006) Development and validation of a PulseNet standardized pulsed-field gel  
411 electrophoresis protocol for subtyping of *Vibrio cholerae*. *Foodborne Pathog Dis* 3: 51-58.
- 412 32. Ichinose Y., Ehara M., Watanabe S., Shimodori S., Waiyaki P., Kibue A., Sang F.C., Ngugi J.,  
413 Kaviti J. (1986) The characterization of *Vibrio cholerae* isolated in Kenya in 1983. *J Trop Med*  
414 *Hyg* 89: 269-276.
- 415 33. Safa A., Nair G.B., Kong R.Y. (2010) Evolution of new variants of *Vibrio cholerae* O1. *Trends*  
416 *Microbiol* 18: 46-54.
- 417 34. Raychoudhuri A., Patra T., Ghosh K., Ramamurthy T., Nandy R.K., Takeda Y., Nair G.B.,  
418 Mukhopadhyay A.K. (2009) Classical ctxB in *Vibrio cholerae* O1, Kolkata, India. *Emerg Infect*  
419 *Dis* 15: 131-132.
- 420 35. Kaper J.B., Morris J.G. Jr., Levine MM. (1995) Cholera. *Clin Microbiol Rev* 8: 48-86.
- 421 36. Colwell R.R., Huq A., Chowdhury M.A., Brayton P.R., Xu B. (1995). Serogroup conversion  
422 of *Vibrio cholerae*. *Can J of Microbiol.* 41: 946-950.
- 423 37. Garg P1, Nandy RK, Chaudhury P, Chowdhury NR, De K, Ramamurthy T, Yamasaki S,  
424 Bhattacharya SK, Takeda Y, Nair GB. (2000). Emergence of *Vibrio cholerae* O1 biotype El  
425 Tor serotype Inaba from the prevailing O1 Ogawa serotype strains in India. *J Clin Microbiol.*  
426 38: 4249-4253.
- 427 38. Manning P.A., Stroehel U.H., Morona R. (1994) Molecular basis for O-antigen biosynthesis in  
428 *Vibrio cholerae* O1: Ogawa-Inaba switching. In: Wachsmuth I., Blake P., Olsvik O. eds. *Vibrio*  
429 *cholerae* and Cholera. Washington DC: ASM Press, pp. 77-94.

- 430 39. Bik E., Bunschoten A., Gouw R., Mooi F. (1995) Genesis of the novel epidemic *Vibrio*  
431 *cholerae* O139 strain: evidence for horizontal transfer of genes involved in polysaccharide  
432 synthesis. *EMBO J* 14: 209-216.
- 433 40. Lu H., Yuan Y., Sun N., Bi Z., Guan B., Shao K., Wang T., Bi Z. (2017) Characterization of  
434 *Vibrio cholerae* isolates from 1976 to 2013 in Shandong Province, China. *Braz J Microbiol* 48:  
435 173-179.
- 436 41. Mutreja A., Kim D.W., Thomson N.R., Connor T.R., Lee J.H., Kariuki S., Croucher N.J., Choi  
437 S.Y., Harris S.R., Lebens M. (2011) Evidence for several waves of global transmission in the  
438 seventh cholera pandemic. *Nature* 477: 462-465.

439

**440 List of abbreviations:**

441 CFR, case fatality rate; CT, cholera toxin; *ctxA*, cholera toxin A subunit gene; *ctxB*, cholera toxin  
442 B subunit gene; *hlyA*, Hemolysin A gene; MIC, minimal inhibitory concentration; PCR,  
443 Polymerase Chain Reaction; PFGE, Pulsed-Field Gel Electrophoresis; RBC Red Blood Cells; RTX,  
444 repeat toxin; *rtxA*, *rtxA* cytotoxin gene; TCP, toxin-coregulated pilus; *toxR*, cholera toxin  
445 transcription activator gene; UPGMA, arithmetic mean algorithm; VP, Voges-Proskauer; VPI-1,  
446 *Vibrio* Pathogenicity Island-1; WHO, World Health Organization

447

448 **Table 1.** Biotypes of the 146 clinical *V. cholerae* O1 isolated from cholera outbreaks in Kenya

Year of isolation (n)	<i>ctxA</i>	Genotype					Phenotype				Biotype
		<i>ctxB</i>	<i>rstR</i>	<i>rtxC</i>	<i>hlyA</i>	<i>rtxA</i>	Phage IV	CCA	PB	VP	
1975 (6)	+	E	E	E	E	E	-	+, 3 (50%)	R	+	El Tor
1980 (6)	+	E	E	E	E	E	-	+, 3 (50%)	R	+	El Tor
1980 (1)	-	-	E	E	E	E	-	-	R	+	El Tor
1981 (4)	+	E	E	E	E	E	-	+, 2 (50%)	R	+	El Tor
1981 (1)	-	-	E	E	E	E	-	-	R	+	El Tor
1982 (5)	+	E	E	E	E	E	-	+, 3 (60%)	R	+	El Tor
1982 (1)	-	-	-	E	E	E	-	-	R	+	El Tor
1983 (4)	+	E	E	E	E	E	-	+, 2 (50%)	R	+	El Tor
1983 (2)	-	-	E	E	E	E	-	+	R	+	El Tor
1984 (4)	+	E	E	E	E	E	-	+, 1 (25%)	R	+	El Tor
1984 (2)	-	-	E	E	E	E	-	+, 1 (50%)	R	+	El Tor
2007 (7)	+, 6 (86%)	E+C	E	E	E	E	-	+	R, 2 (29%)	+	Hybrid
2007 (4)	+	E+C	E	-	E	E	-	+	R, 1 (25%)	+	Hybrid
2007 (1)	-	-	-	E	E	E	-	+	S	+	Unclassified
2008 (1)	+	E+C	E	E	E	E	-	+	R	+	Hybrid
2008 (2)	+	E+C	E	-	E	E	-	+	R	+, 1 (50%)	Hybrid
2008 (1)	-	-	-	E	E	E	-	+	S	+	Unclassified
2008 (1)	-	-	-	-	E	E	-	+	S	+	Unclassified
2009 (7)	+, 4 (57%)	E+C	E	E	E	E	-	+	R, 6 (86%)	+, 3 (43%)	Hybrid
2009 (3)	+, 2 (67%)	E+C	-	E	E	E	-	+, 2 (67%)	R, 1 (33%)	+	Hybrid
2009 (7)	+	E+C	E	-	E	E	-	+	R, 5 (71%)	+, 5 (71%)	Hybrid
2009 (1)	+	E	E	E	E	E	-	-	S	+	Hybrid
2009 (1)	-	E	-	-	E	E	-	+	S	+	Unclassified
2009 (1)	+	C	E	-	E	E	-	+	S	+	Hybrid
2010 (1)	+	E+C	E	-	E	E	-	+	R	+	Hybrid
2010 (2)	+	-	E	-	E	E	-	+	R, 1 (50%)	+	Unclassified
2010 (3)	+	E	-	E	E	E	-	+	R, 1 (33%)	+	El Tor
2010 (1)	+	C	E	-	E	E	-	+	S	-	Hybrid
2015 (53)	+	E+C	E	E	E	E	-	+, 50 (93%)	R, 3 (6%)	+, 30 (56%)	Hybrid
2015 (1)	+	E+C	-	E	E	E	-	+	R	-	Hybrid
2015 (1)	+	E+C	E	-	E	E	-	+	R	-	Hybrid
2015 (1)	+	E	E	E	E	E	-	+	S	+	El Tor
2015 (3)	+	C	E	E	E	E	-	+	S	+	El Tor Variant
2016 (2)	+	E+C	E	E	E	E	-	+	S	-	Hybrid
2016 (1)	+	E+C	E	-	E	E	-	+	S	+	Hybrid
2017 (4)	+	E+C	E	E	E	E	-	+	S	+	Hybrid

449 n, total number of strain(s) of the indicated year; *ctxA*, cholera toxin subunit A; +, present, -, absent

450 *Genotype: ctxB, rtxC, rtxC, hlyA, and rtxA* genes specific for classical or El Tor biotype; +, present,  
451 -, absent; C, classical; E, El Tor

452 *Phenotype:* Phage IV, lysis by classical IV phage; CCA, chicken red blood cell agglutination; PB,  
453 susceptibility to 50 units of Polymyxin B; VP, Voges-Proskauer test; R, resistant, S, sensitive; +,  
454 positive, -, negative

455

456 **Table 2.** Genotypic traits of *V. cholerae* O1 strains isolated from cholera outbreaks in Asian  
 457 countries

Test strain origin	Year of isolation	No. of isolates	Genotypic trait							Biotype
			<i>ctxB</i> type	<i>hlyA</i> type	<i>rstR</i> type	<i>tcpA</i> type	<i>rstC</i>	<i>rtxA</i>	<i>rtxC</i>	
Thailand	1958	1	C	C	C	-	-	+	-	classical
Philippines, Hong Kong, Indonesia	1961	4	E, 3 (75%)	E, 3 (75%)	E	E, 3 (75%)	+, 2 (50%)	+	+, 3 (75%)	El Tor
Taiwan	1962	1	E	E	E	E	+	+	+	El Tor
Philippines	1969	1	-	E	E	E	+	+	+	El Tor
Bangladesh	1980	1	E	E	E	E	+	+	+	El Tor
Philippines	1982	1	E	E	E	E	+	+	+	El Tor
Thailand	1996	1	E	E	-	E	+	+	+	El Tor
Bangladesh	1997	1	E	E	E	E	-	+	+	El Tor
Laos, Thailand	1999	2	C	E	E	E	+	+	+	El Tor variant
Bangladesh	2000	1	C	E	C	E	-	+	+	El Tor variant
Vietnam	2007	1	C	E	E	E	+	+	+	El Tor variant
Vietnam	2008	1	C	E	E	E	+	+	+	El Tor variant
Vietnam	2009	2	C	E	E	E	+	+	+	El Tor variant
Vietnam	2010	1	C	E	E	E	+	+	+	El Tor variant

458 +, present, -, absent; C, classical; E, El Tor

459


460 **Table 3.** Analysis of *V. Cholerae* O1 virulence factors in strains isolated from cholera outbreaks  
 461 in Kenya

Year of isolation (n)	Virulence genes					
	<i>ctxA</i>	<i>tcpA</i>	<i>toxR</i>	<i>rstC</i>	<i>rtxA</i>	<i>hlyA</i>
1975-1984 (36)	+, 29 (81%)	+	+	+, 35 (97%)	+	+
2007-2010 (44)	+, 36 (82%)	+, 29 (66%)	+	+, 30 (68%)	+	+
2015-2017 (66)	+	+, 65 (98%)	+	+, 65 (98%)	+	+

462 n, total number of strain(s) of the indicated year period; *ctxA*, cholera toxin subunit A; *tcpA*, toxin-  
 463 coregulated pilus; *toxR*, cholera toxin transcriptional activator; *rstC*, an antirepressor located in the  
 464 RS1 element of pathogenic *V. cholerae*; *rtxA*, actin-cross-linking repeats-in-toxin (RTX) toxin  
 465 gene; *hlyA*, hemolysin; +, present, -, absent.

466





467

468 **Figure 1:** Pulsed-field gel electrophoresis (PFGE) patterns among 26 Kenya *V. cholerae* O1

469 isolates (1975-2017). Unweighted Pair Group Method with Arithmetic (UPGMA) algorithm

470 differentiated the isolates into 2 clusters (I and II) at 82% similarity cut off and 5 sub-groups (A-

471 E) at 94% similarity cut off. Genotype: +, present; -, absent; C, classical; E, El Tor. Phenotype: +,

472 positive; -, negative; R, resistant; S, sensitive.